Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Company-Sponsored COVID-19 Clinical Study Evaluating a Novel Vaccine Containing Spike and Other SARS-CoV-2 Epitopes as a Boost after First Generation Vaccination (CORAL as a Boost Vaccine Following Vaccination)

Next Previous
X
Search
Trial Profile

A Company-Sponsored COVID-19 Clinical Study Evaluating a Novel Vaccine Containing Spike and Other SARS-CoV-2 Epitopes as a Boost after First Generation Vaccination (CORAL as a Boost Vaccine Following Vaccination)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 vaccines-Gritstone bio (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms CORAL-BARDA
  • Sponsors Gritstone bio

    • Most Recent Events

    • 05 Mar 2024 According to a Gritstone bio media release, in February 2024, the company announced it will incorporate GMP-grade materials in the manufacture of its self-amplifying mRNA (samRNA) candidate, resulting in a delay of the CORAL-BARDA. The move is expected to increase the regulatory utility of the anticipated 10,000 subject, comparative Phase 2b study contracted by the Biomedical Advanced Research and Development Authority (BARDA). Gritstone is now preparing to launch the study in fall of 2024.
    • 29 Feb 2024 According to a Gritstone bio media release, company announced an approximately 40% reduction of its workforce due to which delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.
    • 12 Feb 2024 According to a Gritstone bio media release, the company announced that it is now preparing to launch the Phase 2b head-to-head trial of its next-generation COVID-19 vaccine in the Fall of 2024 rather than 1Q24.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top